Creo Research Development vs Income Tax Expense Analysis

CREO Stock

16.00 0.13 0.81%

Creo Medical financial indicator trend analysis is way more than just evaluating Creo Medical Group prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Creo Medical Group is a good investment. Please check the relationship between Creo Medical Research Development and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Creo Medical Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Research Development vs Income Tax Expense

Research Development vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Creo Medical Group Research Development account and Income Tax Expense. At this time, the significance of the direction appears to have pay attention.

The correlation between Creo Medical's Research Development and Income Tax Expense is -0.94. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Creo Medical Group, assuming nothing else is changed. The correlation between historical values of Creo Medical's Research Development and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Creo Medical Group are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Research Development i.e., Creo Medical's Research Development and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Research Development

Income Tax Expense

Most indicators from Creo Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Creo Medical Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Creo Medical Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 42.5 M in 2024, whereas Tax Provision is likely to drop (2.9 M) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	237K	248K	400K	420K
Depreciation And Amortization	2.6M	3.1M	3.4M	3.6M

Interest Expense Depreciation And Amortization

Creo Medical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Short Term Investments	Total Liab	Property Plant Equipment	Other Liab	Cash	Net Receivables	Total Stockholder Equity	Retained Earnings	Inventory	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Total Current Assets	Common Stock
Total Assets		0.85	0.83	0.8	0.38	0.86	0.77	0.95	0.66	0.88	0.95	-0.77	0.84	0.77	-0.41	0.81	-0.64	0.69	0.87	0.7	0.78	0.86	0.91	0.71	0.91	0.76
Other Current Liab	0.85		0.99	0.85	0.06	0.95	0.67	0.71	0.5	0.62	0.78	-0.61	0.83	0.7	-0.26	0.82	-0.93	0.46	0.65	0.47	0.92	0.74	0.68	0.61	0.7	0.47
Total Current Liabilities	0.83	0.99		0.89	0.11	0.97	0.72	0.72	0.42	0.66	0.76	-0.67	0.87	0.76	-0.18	0.86	-0.92	0.39	0.66	0.52	0.95	0.78	0.72	0.67	0.65	0.51
Accounts Payable	0.8	0.85	0.89		0.34	0.91	0.87	0.75	0.23	0.81	0.67	-0.84	0.94	0.91	-0.09	0.92	-0.77	0.37	0.81	0.69	0.85	0.89	0.83	0.86	0.54	0.69
Short Term Investments	0.38	0.06	0.11	0.34		0.3	0.71	0.52	-0.24	0.69	0.21	-0.78	0.55	0.63	0.36	0.57	0.23	0.0	0.49	0.89	0.27	0.3	0.68	0.71	0.13	0.88
Total Liab	0.86	0.95	0.97	0.91	0.3		0.81	0.78	0.33	0.76	0.73	-0.78	0.94	0.84	-0.07	0.94	-0.85	0.36	0.72	0.68	0.97	0.76	0.81	0.77	0.62	0.65
Property Plant Equipment	0.77	0.67	0.72	0.87	0.71	0.81		0.8	0.06	0.88	0.6	-0.97	0.96	0.99	0.17	0.96	-0.47	0.2	0.74	0.92	0.74	0.76	0.93	0.99	0.46	0.89
Other Liab	0.95	0.71	0.72	0.75	0.52	0.78	0.8		0.56	0.93	0.89	-0.82	0.83	0.79	-0.3	0.8	-0.5	0.61	0.88	0.79	0.71	0.84	0.95	0.76	0.84	0.84
Cash	0.66	0.5	0.42	0.23	-0.24	0.33	0.06	0.56		0.36	0.81	-0.08	0.18	0.07	-0.89	0.12	-0.4	0.89	0.51	0.01	0.27	0.51	0.34	-0.02	0.91	0.15
Net Receivables	0.88	0.62	0.66	0.81	0.69	0.76	0.88	0.93	0.36		0.78	-0.94	0.87	0.86	-0.18	0.84	-0.39	0.54	0.93	0.89	0.69	0.85	0.97	0.85	0.7	0.95
Total Stockholder Equity	0.95	0.78	0.76	0.67	0.21	0.73	0.6	0.89	0.81	0.78		-0.62	0.68	0.6	-0.58	0.64	-0.59	0.79	0.81	0.53	0.67	0.84	0.79	0.54	0.97	0.62
Retained Earnings	-0.77	-0.61	-0.67	-0.84	-0.78	-0.78	-0.97	-0.82	-0.08	-0.94	-0.62		-0.93	-0.96	-0.12	-0.92	0.39	-0.26	-0.8	-0.96	-0.72	-0.78	-0.95	-0.97	-0.48	-0.95
Inventory	0.84	0.83	0.87	0.94	0.55	0.94	0.96	0.83	0.18	0.87	0.68	-0.93		0.96	0.08	1.0	-0.68	0.27	0.77	0.85	0.89	0.79	0.92	0.93	0.55	0.82
Property Plant And Equipment Net	0.77	0.7	0.76	0.91	0.63	0.84	0.99	0.79	0.07	0.86	0.6	-0.96	0.96		0.16	0.96	-0.55	0.19	0.73	0.88	0.76	0.79	0.92	0.99	0.45	0.85
Net Debt	-0.41	-0.26	-0.18	-0.09	0.36	-0.07	0.17	-0.3	-0.89	-0.18	-0.58	-0.12	0.08	0.16		0.14	0.2	-0.92	-0.43	0.21	-0.01	-0.41	-0.09	0.23	-0.71	0.03
Non Current Assets Total	0.81	0.82	0.86	0.92	0.57	0.94	0.96	0.8	0.12	0.84	0.64	-0.92	1.0	0.96	0.14		-0.66	0.21	0.73	0.86	0.9	0.75	0.9	0.93	0.5	0.81
Non Currrent Assets Other	-0.64	-0.93	-0.92	-0.77	0.23	-0.85	-0.47	-0.5	-0.4	-0.39	-0.59	0.39	-0.68	-0.55	0.2	-0.66		-0.3	-0.45	-0.21	-0.83	-0.62	-0.46	-0.44	-0.51	-0.18
Cash And Short Term Investments	0.69	0.46	0.39	0.37	0.0	0.36	0.2	0.61	0.89	0.54	0.79	-0.26	0.27	0.19	-0.92	0.21	-0.3		0.73	0.19	0.27	0.64	0.45	0.13	0.88	0.36
Common Stock Total Equity	0.87	0.65	0.66	0.81	0.49	0.72	0.74	0.88	0.51	0.93	0.81	-0.8	0.77	0.73	-0.43	0.73	-0.45	0.73		0.71	0.64	0.91	0.86	0.7	0.77	0.82
Common Stock Shares Outstanding	0.7	0.47	0.52	0.69	0.89	0.68	0.92	0.79	0.01	0.89	0.53	-0.96	0.85	0.88	0.21	0.86	-0.21	0.19	0.71		0.63	0.61	0.91	0.91	0.42	0.97
Non Current Liabilities Total	0.78	0.92	0.95	0.85	0.27	0.97	0.74	0.71	0.27	0.69	0.67	-0.72	0.89	0.76	-0.01	0.9	-0.83	0.27	0.64	0.63		0.68	0.73	0.69	0.55	0.58
Other Current Assets	0.86	0.74	0.78	0.89	0.3	0.76	0.76	0.84	0.51	0.85	0.84	-0.78	0.79	0.79	-0.41	0.75	-0.62	0.64	0.91	0.61	0.68		0.84	0.75	0.75	0.7
Other Stockholder Equity	0.91	0.68	0.72	0.83	0.68	0.81	0.93	0.95	0.34	0.97	0.79	-0.95	0.92	0.92	-0.09	0.9	-0.46	0.45	0.86	0.91	0.73	0.84		0.91	0.7	0.94
Property Plant And Equipment Gross	0.71	0.61	0.67	0.86	0.71	0.77	0.99	0.76	-0.02	0.85	0.54	-0.97	0.93	0.99	0.23	0.93	-0.44	0.13	0.7	0.91	0.69	0.75	0.91		0.39	0.87
Total Current Assets	0.91	0.7	0.65	0.54	0.13	0.62	0.46	0.84	0.91	0.7	0.97	-0.48	0.55	0.45	-0.71	0.5	-0.51	0.88	0.77	0.42	0.55	0.75	0.7	0.39		0.53
Common Stock	0.76	0.47	0.51	0.69	0.88	0.65	0.89	0.84	0.15	0.95	0.62	-0.95	0.82	0.85	0.03	0.81	-0.18	0.36	0.82	0.97	0.58	0.7	0.94	0.87	0.53

Click cells to compare fundamentals

Creo Medical Account Relationship Matchups

Creo Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.3M	92.5M	100.6M	75.3M	76.6M	80.4M
Other Current Liab	3.2M	9.4M	10.3M	7.5M	3.8M	2.7M
Total Current Liabilities	5.1M	18.0M	19.7M	17.5M	9.9M	5.3M
Accounts Payable	923.3K	2.5M	3.5M	4.3M	2.5M	2.6M
Total Liab	5.6M	29.7M	27.3M	25.9M	16.8M	17.6M
Property Plant Equipment	906.3K	1.3M	3.4M	8.6M	9.9M	10.4M
Cash	81.0M	45.1M	43.5M	13.1M	3M	2.9M
Net Receivables	4.1M	4.2M	3.9M	5M	6.4M	6.7M
Total Stockholder Equity	82.7M	62.8M	73.3M	49.4M	59.8M	31.8M
Retained Earnings	(37.2M)	(57.6M)	(82.2M)	(109.1M)	(144.4M)	(137.2M)
Inventory	727.2K	6.8M	8.5M	9.3M	8.1M	8.5M
Property Plant And Equipment Net	1.3M	3.4M	8.6M	10.2M	9.1M	9.6M
Net Debt	(80.3M)	(32.7M)	(33.0M)	(3.0M)	5.3M	5.6M
Non Current Assets Total	2.2M	33.0M	39.4M	41.7M	38.7M	40.6M
Non Currrent Assets Other	(2.0M)	(18.3M)	(18.6M)	(19.6M)	200K	210K
Cash And Short Term Investments	81.0M	45.1M	43.5M	13.1M	18.5M	26.4M
Common Stock Shares Outstanding	125.8M	161.6M	170.4M	187.9M	313.0M	328.7M
Liabilities And Stockholders Equity	88.3M	92.5M	100.6M	75.3M	76.6M	55.6M
Non Current Liabilities Total	543.9K	11.6M	7.6M	8.5M	6.9M	3.9M
Other Current Assets	4.3M	3.3M	5.3M	6.3M	4.9M	3.5M
Other Stockholder Equity	101.5M	101.7M	135.8M	149.5M	180.9M	189.9M
Total Current Assets	86.1M	59.5M	61.2M	33.7M	37.9M	32.9M
Accumulated Other Comprehensive Income	4.6M	4.9M	5.8M	8.8M	22.9M	24.0M
Common Stock	150.4K	158K	181K	182K	400K	420K
Net Tangible Assets	47.4M	81.9M	34.8M	46.4M	53.4M	29.1M
Other Assets	19.3K	128.4K	1.1M	1.0	1.15	1.09
Short Long Term Debt Total	717.1K	12.4M	10.6M	10.1M	8.3M	5.2M
Long Term Debt	357.3K	5.2M	3.8M	4.9M	4.4M	2.4M
Short Long Term Debt	173.2K	5.2M	4.7M	1.6M	2.5M	1.6M
Short Term Debt	173.2K	5.8M	5.4M	4.6M	3.1M	2.2M
Intangible Assets	865.2K	28.5M	27.3M	27.6M	7.1M	10.1M
Current Deferred Revenue	(4.0M)	161K	214K	(200K)	(230K)	(241.5K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Creo Stock Analysis

When running Creo Medical's price analysis, check to measure Creo Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Creo Medical is operating at the current time. Most of Creo Medical's value examination focuses on studying past and present price action to predict the probability of Creo Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Creo Medical's price. Additionally, you may evaluate how the addition of Creo Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Creo Research Development vs Income Tax Expense Analysis

Research Development vs Income Tax Expense

Research Development vs Income Tax Expense Correlation Analysis

Correlation Coefficient

Research Development

Income Tax Expense

Creo Medical fundamental ratios Correlations

Creo Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Creo Medical fundamental ratios Accounts

Also Currently Popular

Additional Tools for Creo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Inventory
Total Current Liabilities	+ 0.99	Other Current Liab
Property Plant And Equipment Net	+ 0.99	Property Plant Equipment
Property Plant And Equipment Gross	+ 0.99	Property Plant Equipment
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.97	Total Current Liabilities

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant Equipment
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Property Plant And Equipment Net	- 0.96	Retained Earnings
Common Stock	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings